187 related articles for article (PubMed ID: 35759908)
1. Discovery of pomalidomide-based PROTACs for selective degradation of histone deacetylase 8.
Sun Z; Deng B; Yang Z; Mai R; Huang J; Ma Z; Chen T; Chen J
Eur J Med Chem; 2022 Sep; 239():114544. PubMed ID: 35759908
[TBL] [Abstract][Full Text] [Related]
2. Induced protein degradation of histone deacetylases 3 (HDAC3) by proteolysis targeting chimera (PROTAC).
Cao F; de Weerd S; Chen D; Zwinderman MRH; van der Wouden PE; Dekker FJ
Eur J Med Chem; 2020 Dec; 208():112800. PubMed ID: 32971411
[TBL] [Abstract][Full Text] [Related]
3. Discovery of highly potent HDAC8 PROTACs with anti-tumor activity.
Zhao C; Chen D; Suo F; Setroikromo R; Quax WJ; Dekker FJ
Bioorg Chem; 2023 Jul; 136():106546. PubMed ID: 37098288
[TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis and Biological Characterization of Histone Deacetylase 8 (HDAC8) Proteolysis Targeting Chimeras (PROTACs) with Anti-Neuroblastoma Activity.
Darwish S; Ghazy E; Heimburg T; Herp D; Zeyen P; Salem-Altintas R; Ridinger J; Robaa D; Schmidtkunz K; Erdmann F; Schmidt M; Romier C; Jung M; Oehme I; Sippl W
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886887
[TBL] [Abstract][Full Text] [Related]
5. Selective degradation of histone deacetylase 8 mediated by a proteolysis targeting chimera (PROTAC).
Chotitumnavee J; Yamashita Y; Takahashi Y; Takada Y; Iida T; Oba M; Itoh Y; Suzuki T
Chem Commun (Camb); 2022 Apr; 58(29):4635-4638. PubMed ID: 35311871
[TBL] [Abstract][Full Text] [Related]
6. Solid-Phase Synthesis of Cereblon-Recruiting Selective Histone Deacetylase 6 Degraders (HDAC6 PROTACs) with Antileukemic Activity.
Sinatra L; Yang J; Schliehe-Diecks J; Dienstbier N; Vogt M; Gebing P; Bachmann LM; Sönnichsen M; Lenz T; Stühler K; Schöler A; Borkhardt A; Bhatia S; Hansen FK
J Med Chem; 2022 Dec; 65(24):16860-16878. PubMed ID: 36473103
[TBL] [Abstract][Full Text] [Related]
7. Effective degradation of EGFR
Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
[TBL] [Abstract][Full Text] [Related]
8. Development of a Bestatin-SAHA Hybrid with Dual Inhibitory Activity against APN and HDAC.
Cao J; Zhao W; Zhao C; Liu Q; Li S; Zhang G; Chou CJ; Zhang Y
Molecules; 2020 Oct; 25(21):. PubMed ID: 33126591
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors.
Suzuki T; Muto N; Bando M; Itoh Y; Masaki A; Ri M; Ota Y; Nakagawa H; Iida S; Shirahige K; Miyata N
ChemMedChem; 2014 Mar; 9(3):657-64. PubMed ID: 24403121
[TBL] [Abstract][Full Text] [Related]
10. HDAC3 and HDAC8 PROTAC dual degrader reveals roles of histone acetylation in gene regulation.
Xiao Y; Hale S; Awasthee N; Meng C; Zhang X; Liu Y; Ding H; Huo Z; Lv D; Zhang W; He M; Zheng G; Liao D
Cell Chem Biol; 2023 Nov; 30(11):1421-1435.e12. PubMed ID: 37572669
[TBL] [Abstract][Full Text] [Related]
11. Attenuation of NLRP3 Inflammasome Activation by Indirubin-Derived PROTAC Targeting HDAC6.
Cao Z; Gu Z; Lin S; Chen D; Wang J; Zhao Y; Li Y; Liu T; Li Y; Wang Y; Lin H; He B
ACS Chem Biol; 2021 Dec; 16(12):2746-2751. PubMed ID: 34860497
[TBL] [Abstract][Full Text] [Related]
12. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
13. A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors.
Fontana A; Cursaro I; Carullo G; Gemma S; Butini S; Campiani G
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077415
[TBL] [Abstract][Full Text] [Related]
14. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y
Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873
[TBL] [Abstract][Full Text] [Related]
15. Identification of a Histone Deacetylase 8 Inhibitor through Drug Screenings Based on Machine Learning.
Nurani A; Yamashita Y; Taki Y; Takada Y; Itoh Y; Suzuki T
Chem Pharm Bull (Tokyo); 2024; 72(2):173-178. PubMed ID: 38296560
[TBL] [Abstract][Full Text] [Related]
16. Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs.
Xiao Y; Wang J; Zhao LY; Chen X; Zheng G; Zhang X; Liao D
Chem Commun (Camb); 2020 Aug; 56(68):9866-9869. PubMed ID: 32840532
[TBL] [Abstract][Full Text] [Related]
17. Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity.
Wu H; Yang K; Zhang Z; Leisten ED; Li Z; Xie H; Liu J; Smith KA; Novakova Z; Barinka C; Tang W
J Med Chem; 2019 Aug; 62(15):7042-7057. PubMed ID: 31271281
[TBL] [Abstract][Full Text] [Related]
18. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.
Wang Y; Wallach J; Duane S; Wang Y; Wu J; Wang J; Adejare A; Ma H
Drug Des Devel Ther; 2017; 11():1369-1382. PubMed ID: 28496307
[TBL] [Abstract][Full Text] [Related]
19. Designing HDAC-PROTACs: lessons learned so far.
Fischer F; Alves Avelar LA; Murray L; Kurz T
Future Med Chem; 2022 Jan; 14(3):143-166. PubMed ID: 34951318
[TBL] [Abstract][Full Text] [Related]
20. PROTAC-mediated degradation of class I histone deacetylase enzymes in corepressor complexes.
Smalley JP; Adams GE; Millard CJ; Song Y; Norris JKS; Schwabe JWR; Cowley SM; Hodgkinson JT
Chem Commun (Camb); 2020 Apr; 56(32):4476-4479. PubMed ID: 32201871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]